Cantor Fitzgerald Comments on Marinus Pharmaceuticals, Inc.’s FY2024 Earnings (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) – Research analysts at Cantor Fitzgerald decreased their FY2024 earnings per share estimates for shares of Marinus Pharmaceuticals in a research note issued on Tuesday, April 16th. Cantor Fitzgerald analyst C. Duncan now forecasts that the biopharmaceutical company will earn ($2.32) per share for the year, down from their previous estimate of ($2.13). Cantor Fitzgerald currently has a “Overweight” rating and a $28.00 target price on the stock. The consensus estimate for Marinus Pharmaceuticals’ current full-year earnings is ($2.37) per share.

A number of other equities research analysts have also recently weighed in on MRNS. Robert W. Baird restated a “neutral” rating on shares of Marinus Pharmaceuticals in a research note on Tuesday. Royal Bank of Canada restated a “sector perform” rating and issued a $3.00 price target (down previously from $24.00) on shares of Marinus Pharmaceuticals in a research note on Monday. StockNews.com cut Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. Oppenheimer restated a “market perform” rating and issued a $9.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, March 7th. Finally, HC Wainwright restated a “buy” rating and issued a $27.00 price target on shares of Marinus Pharmaceuticals in a research note on Tuesday. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Marinus Pharmaceuticals has an average rating of “Hold” and an average price target of $18.21.

Marinus Pharmaceuticals Trading Up 20.0 %

MRNS opened at $1.44 on Thursday. Marinus Pharmaceuticals has a 1-year low of $1.11 and a 1-year high of $11.26. The stock’s fifty day simple moving average is $8.72 and its 200 day simple moving average is $8.45. The company has a debt-to-equity ratio of 5.68, a quick ratio of 4.01 and a current ratio of 4.07.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its quarterly earnings data on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.10). The company had revenue of $7.19 million during the quarter, compared to analyst estimates of $7.78 million. Marinus Pharmaceuticals had a negative net margin of 456.31% and a negative return on equity of 269.75%. During the same period in the previous year, the company posted ($0.76) EPS.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Marinus Pharmaceuticals by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 2,577,475 shares of the biopharmaceutical company’s stock worth $20,749,000 after buying an additional 31,233 shares during the period. Schonfeld Strategic Advisors LLC grew its holdings in shares of Marinus Pharmaceuticals by 69.5% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 253,412 shares of the biopharmaceutical company’s stock worth $2,040,000 after purchasing an additional 103,935 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its holdings in shares of Marinus Pharmaceuticals by 6.3% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 2,904,476 shares of the biopharmaceutical company’s stock worth $23,381,000 after purchasing an additional 173,226 shares in the last quarter. Jennison Associates LLC grew its holdings in shares of Marinus Pharmaceuticals by 58.4% during the 3rd quarter. Jennison Associates LLC now owns 2,955,343 shares of the biopharmaceutical company’s stock worth $23,791,000 after purchasing an additional 1,089,913 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Marinus Pharmaceuticals by 383.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,307 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 5,003 shares in the last quarter. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.